Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Van Meter

Showing results (51-60 of 65) with videos related to

Pageof 7
Sort By:
The Journal of Clinical Psychiatry|November 7, 2014
Six-month outcomes from a randomized trial augmenting serotonin reuptake inhibitors with exposure and response prevention or risperidone in adults with obsessive-compulsive disorderEdna B Foa, Helen Blair Simpson, David Rosenfield, et al.
JAMA Psychiatry|September 13, 2013
Cognitive-behavioral therapy vs risperidone for augmenting serotonin reuptake inhibitors in obsessive-compulsive disorder: a randomized clinical trialHelen Blair Simpson, Edna B Foa, Michael R Liebowitz, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|May 4, 2026
Pre-analytical guidelines for blood and CSF Biomarkers 2025: Recommendations from the NACC ADRC Biofluid Biomarker Best Practices WorkgroupTimothy E Van Meter, Edward N Wilson, Fanny Elahi, et al.
Journal of Neurotrauma|January 20, 2025
Prospective Harmonization, Common Data Elements, and Sharing Strategies for Multicenter Pre-Clinical Traumatic Brain Injury Research in the Translational Outcomes Project in Neurotrauma ConsortiumIna-Beate Wanner, Joseph T McCabe, J Russell Huie, et al.
Molecular Psychiatry|January 16, 2024
Age of onset of obsessive-compulsive disorder differentially affects white matter microstructureChris Vriend, Niels T de Joode, Petra J W Pouwels, et al.
JAMA Psychiatry|January 26, 2022
Maintenance of Wellness in Patients With Obsessive-Compulsive Disorder Who Discontinue Medication After Exposure/Response Prevention Augmentation: A Randomized Clinical TrialEdna B Foa, Helen Blair Simpson, Thea Gallagher, et al.
Behaviour Research and Therapy|June 5, 2021
Maximizing remission from cognitive-behavioral therapy in medicated adults with obsessive-compulsive disorderHelen B Simpson, Edna B Foa, Michael G Wheaton, et al.
Cancer Cell|July 10, 2019
A C19MC-LIN28A-MYCN Oncogenic Circuit Driven by Hijacked Super-enhancers Is a Distinct Therapeutic Vulnerability in ETMRs: A Lethal Brain TumorPatrick Sin-Chan, Iqra Mumal, Tannu Suwal, et al.
The Lancet. Oncology|April 18, 2015
Molecular subgroups of atypical teratoid rhabdoid tumours in children: an integrated genomic and clinicopathological analysisJonathon Torchia, Daniel Picard, Lucie Lafay-Cousin, et al.
Acta Neuropathologica|November 1, 2013
TERT promoter mutations are highly recurrent in SHH subgroup medulloblastomaMarc Remke, Vijay Ramaswamy, John Peacock, et al.
Pageof 7

Showing results (51-60 of 65) with videos related to

Sort By:
Pageof 7
The Journal of Clinical Psychiatry|November 7, 2014
Six-month outcomes from a randomized trial augmenting serotonin reuptake inhibitors with exposure and response prevention or risperidone in adults with obsessive-compulsive disorderEdna B Foa, Helen Blair Simpson, David Rosenfield, et al.
JAMA Psychiatry|September 13, 2013
Cognitive-behavioral therapy vs risperidone for augmenting serotonin reuptake inhibitors in obsessive-compulsive disorder: a randomized clinical trialHelen Blair Simpson, Edna B Foa, Michael R Liebowitz, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|May 4, 2026
Pre-analytical guidelines for blood and CSF Biomarkers 2025: Recommendations from the NACC ADRC Biofluid Biomarker Best Practices WorkgroupTimothy E Van Meter, Edward N Wilson, Fanny Elahi, et al.
Journal of Neurotrauma|January 20, 2025
Prospective Harmonization, Common Data Elements, and Sharing Strategies for Multicenter Pre-Clinical Traumatic Brain Injury Research in the Translational Outcomes Project in Neurotrauma ConsortiumIna-Beate Wanner, Joseph T McCabe, J Russell Huie, et al.
Molecular Psychiatry|January 16, 2024
Age of onset of obsessive-compulsive disorder differentially affects white matter microstructureChris Vriend, Niels T de Joode, Petra J W Pouwels, et al.
JAMA Psychiatry|January 26, 2022
Maintenance of Wellness in Patients With Obsessive-Compulsive Disorder Who Discontinue Medication After Exposure/Response Prevention Augmentation: A Randomized Clinical TrialEdna B Foa, Helen Blair Simpson, Thea Gallagher, et al.
Behaviour Research and Therapy|June 5, 2021
Maximizing remission from cognitive-behavioral therapy in medicated adults with obsessive-compulsive disorderHelen B Simpson, Edna B Foa, Michael G Wheaton, et al.
Cancer Cell|July 10, 2019
A C19MC-LIN28A-MYCN Oncogenic Circuit Driven by Hijacked Super-enhancers Is a Distinct Therapeutic Vulnerability in ETMRs: A Lethal Brain TumorPatrick Sin-Chan, Iqra Mumal, Tannu Suwal, et al.
The Lancet. Oncology|April 18, 2015
Molecular subgroups of atypical teratoid rhabdoid tumours in children: an integrated genomic and clinicopathological analysisJonathon Torchia, Daniel Picard, Lucie Lafay-Cousin, et al.
Acta Neuropathologica|November 1, 2013
TERT promoter mutations are highly recurrent in SHH subgroup medulloblastomaMarc Remke, Vijay Ramaswamy, John Peacock, et al.
Pageof 7